hl237
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2017 (NCT03278470)
Timeline
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04638426 | Phase 2 | Sep 10, 2020 | Hanlim Pharm. Co., Ltd. |
| NCT04633733 | Phase 1 | Aug 22, 2020 | Hanlim Pharm. Co., Ltd. |
| NCT03896594 | Phase 1 | Dec 24, 2018 | Hanlim Pharm. Co., Ltd. |
| NCT03278470 | Phase 1 | Jun 26, 2017 | Hanlim Pharm. Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanlim Pharm. Co., Ltd. | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1